Halda Therapeutics has raised $126M across 2 funding rounds, plus 1 undated round. The company is valued at $250M.
Halda Therapeutics was backed by investors including Khosla Ventures and DCVC before Johnson & Johnson agreed in November 2025 to acquire the company for $3.05 billion in cash, adding its RIPTAC platform to J&J's oncology pipeline.
2 funding rounds, the latest highlighted.
No date is disclosed for this round.
Elm Street Ventures. Led by Canaan Partners.
No filing has been made.
2 dated rounds, newest first.
Access IndustriesLEAD
Canaan PartnersLEAD
Khosla Ventures
DCVCLead investors for each round are in the funding timeline.
The closest biotechnology peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Halda Therapeutics is a private company; its shares do not trade on a public exchange.
The last valuation is $250M.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
